Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
复制标题
DOI：
10.1038/s41591-021-01294-w
复制
发表时间：
2021-04
期刊：
影响因子：
82.9
通讯作者：
Diamond MS
中科院分区：
文献类型：
--
作者：
Chen RE;Zhang X;Case JB;Winkler ES;Liu Y;VanBlargan LA;Liu J;Errico JM;Xie X;Suryadevara N;Gilchuk P;Zost SJ;Tahan S;Droit L;Turner JS;Kim W;Schmitz AJ;Thapa M;Wang D;Boon ACM;Presti RM;O'Halloran JA;Kim AHJ;Deepak P;Pinto D;Fremont DH;Crowe JE Jr;Corti D;Virgin HW;Ellebedy AH;Shi PY;Diamond MS
严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起了全球 COVID-19 大流行。快速传播的 SARS-CoV-2 变种可能会危及新推出的抗体和疫苗对策。在这里，我们使用单克隆抗体 (mAb)、动物免疫血清、人类恢复期血清和 BNT162b2 mRNA 疫苗接受者的人类血清，报告了一组真实的 SARS-CoV-2 变体（包括 B.1.1.7 分离株、具有南非或巴西刺突基因的嵌合毒株以及同基因重组病毒变体）对抗体中和的影响。许多与受体结合结构域 (RBD) 或 N 末端结构域 (NTD) 结合的高度中和性 mAb，以及大多数恢复期血清和 mRNA 疫苗诱导的免疫血清，显示出对含有 E484K 尖峰突变的病毒的抑制活性降低。由于与刺突 RBD 和 NTD 结合的抗体在体外对某些新兴变体的中和效力减弱，因此可能需要针对高度保守区域的更新 mAb 混合物、增强 mAb 效力或调整疫苗的刺突序列，以防止体内保护丧失。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly-spreading SARS-CoV-2 variants may jeopardize newly-introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera, and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes, and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor binding domain (RBD) or N-terminal domain (NTD), and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike RBD and NTD demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency, or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
DOI：
10.4049/jimmunol.2000583
发表时间：
2020-08-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Alsoussi WB;Turner JS;Case JB;Zhao H;Schmitz AJ;Zhou JQ;Chen RE;Lei T;Rizk AA;McIntire KM;Winkler ES;Fox JM;Kafai NM;Thackray LB;Hassan AO;Amanat F;Krammer F;Watson CT;Kleinstein SH;Fremont DH;Diamond MS;Ellebedy AH
通讯作者：
Ellebedy AH
影响因子：
64.5
作者：
Dejnirattisai W;Zhou D;Ginn HM;Duyvesteyn HME;Supasa P;Case JB;Zhao Y;Walter TS;Mentzer AJ;Liu C;Wang B;Paesen GC;Slon-Campos J;López-Camacho C;Kafai NM;Bailey AL;Chen RE;Ying B;Thompson C;Bolton J;Fyfe A;Gupta S;Tan TK;Gilbert-Jaramillo J;James W;Knight M;Carroll MW;Skelly D;Dold C;Peng Y;Levin R;Dong T;Pollard AJ;Knight JC;Klenerman P;Temperton N;Hall DR;Williams MA;Paterson NG;Bertram FKR;Siebert CA;Clare DK;Howe A;Radecke J;Song Y;Townsend AR;Huang KA;Fry EE;Mongkolsapaya J;Diamond MS;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
DOI：
10.1016/j.xcrm.2021.100230
发表时间：
2021-04-20
期刊：
Cell reports. Medicine
影响因子：
--
作者：
Hassan AO;Feldmann F;Zhao H;Curiel DT;Okumura A;Tang-Huau TL;Case JB;Meade-White K;Callison J;Chen RE;Lovaglio J;Hanley PW;Scott DP;Fremont DH;Feldmann H;Diamond MS
通讯作者：
Diamond MS
影响因子：
1.2
作者：
Cingolani, Pablo;Platts, Adrian;Ruden, Douglas M.
通讯作者：
Ruden, Douglas M.